Baystate Medical Center

- KOLs to provide insight and discussion of EYP-1901 in wet AMD and topline data considerations for the DAVIO 2 clinical trial WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET. This event will focus on the potential of EYP-1901 in wet age-related macular degeneration (wet AMD), including KOL perspectives on the current wet AMD treatment landscape, vorolanib’s unique mechanism of action and outcome considerations for the upcoming topline data read-out for the DAVIO 2 trial in December. The event will be moderated by EyePoint’s President and Chief Executive Officer, Jay S. Duker, M.D., and will feature presentations from the following retinal experts: David S. Boyer, M.D., Senior Partner at Retina-Vitreous Associates Medical Group, Adjunct Clinical Professor of Ophthalmology at University of Southern California, Keck School of MedicineDavid R. Lally, M.D., Retinal Surgeon at Baystate Medical Center, Assistant Professor of Ophthalmology at the University of Massachusetts Medical School-Baystate, Director of Retina Research Institute at New England Retinal Consultants To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI7011e8a8a96a408b91e23c1c3f598ede. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EYP-1901 EYP-1901 is being developed as an investigational sustained delivery treatment for retinal disease combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology (Durasert E™) with vorolanib, a tyrosine kinase inhibitor. Results from the Phase 1 DAVIO clinical trial of EYP-1901 in wet AMD showed a positive safety profile with stable visual acuity and OCT. Further, the data demonstrated an impressive treatment burden reduction of 75% at six months and 73% at the 12-month visit following a single dose of EYP-1901. Phase 2 trials are fully enrolled in wet AMD and non-proliferative diabetic retinopathy, and a diabetic macular edema trial is planned for initiation in Q1 2024. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to over 80,000 patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com. Investors:Christina TartagliaStern IRDirect: 212-698-8700christina.tartaglia@sternir.com Media Contact:Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com

Labcorp will acquire Baystate Health’s outreach laboratory business, select operating assets, and collaborate with Baystate Health to improve access and enhance affordable, high-quality healthcare services for underserved communities in Massachusetts Baystate Health operates laboratory service centres in Massachusetts. (Credit: Julia Koblitz on Unsplash) US-based laboratory services provider Labcorp has unveiled its plans to acquire Baystate Health’s outreach laboratory business and select operating assets, for an undisclosed sum. Baystate Health is a not-for-profit, integrated healthcare system that serves around 800,000 people throughout the western New England region. The select operating assets to be acquired by Labcorp include laboratory service centres operated by Baystate Health throughout Massachusetts. The acquisition builds on the existing reference laboratory relationship between Labcorp and Baystate Health to improve routine and speciality lab testing. Labcorp will open a regional laboratory at the existing Baystate Health location in Holyoke, Massachusetts, to provide professional services for anatomic pathology and speciality testing. The acquisition is expected to be completed in early 2024, subject to certain customary closing conditions and regulatory approvals. Labcorp Northeast Division senior vice president Bill Haas said: “Labcorp is focused on delivering high-quality, cost-effective laboratory testing to health systems, physicians, patients, health plans and communities we serve. “We are thrilled to grow our important relationship with Baystate Health and to realize our shared vision to enhance the patient and provider experience in the communities Baystate serves.” Baystate Health hospital operations senior vice president and Baystate Medical Centre president Sam Skura said: “For many years, Labcorp has served as our trusted primary reference testing provider, and we are confident they will continue to deliver high-quality outcomes, affordable access, and optimal service for our patients and providers.” In addition to the acquisition, Labcorp will collaborate with Baystate Health to enhance affordable, high-quality healthcare services for underserved communities throughout the region. The strategic partnership aims to improve access to testing for patients and providers, standardise laboratory testing, and expand the ability to deliver timely results. According to Labcorp, the acquisition will leverage key capabilities, experience, and technologies from both companies to advance the delivery of high-quality patient care. It will combine Labcorp’s clinical laboratory services, data, and digital tools, with continued patient access through the network of Baystate’s patient service centres. Baystate Health president and CEO Mark Keroack said: “This collaboration is fully aligned with Baystate Health’s mission to improve the health of the people in our communities every day, with quality and compassion. “Labcorp believes in our mission and will continue to deliver a high level of service with plans to make capital investments in structure and process to deliver laboratory services to our patient population in more innovative and efficient ways.”

PHILADELPHIA--( BUSINESS WIRE )-- iECURE , a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment of Gabriel M. Cohn, M.D., MBA as Chief Medical Officer. Dr. Cohn will lead iECURE’s clinical strategy for the company’s pipeline of in vivo gene editing therapies, including those designed to treat Ornithine Transcarbamylase (OTC) deficiency, citrullinemia type 1 (CTLN1), and phenylketonuria (PKU). “Gabe’s experience in clinical development as a CMO will be crucial as we begin the process of global regulatory submissions and patient dosing. His diverse experiences in clinical development and gene therapy paired with a robust understanding of genetic disorders and leadership roles in the industry make him the ideal person to take the reins of our expanding clinical team,” said Joseph Truitt, Chief Executive Officer of iECURE. Dr. Cohn brings more than 30 years of experience in academic medicine as well as in the biotechnology industry, where he has contributed to the development of multiple therapeutics for the treatment of rare genetic disorders. Previously, he served as the Chief Medical Officer of Homology Medicines where he led the company’s Phase 1/2 gene therapy trial for PKU and supported two investigational new drug (IND) submissions to U.S. Food and Drug Administration (FDA) for the company’s gene editing programs. Before joining Homology, he served as Vice President of Clinical Development at AVROBIO, leading clinical programs, protocol design, regulatory filings, FDA and Health Canada interactions and trial site identification and initiations. He has also served in executive leadership roles at OvaScience and Shire. Dr. Cohn is a Fellow of the American College of Genetics and Genomics (FACMG) and the American College of Obstetrics and Gynecology (ACOG), author of over 40 peer-reviewed publications, and served as the Chief of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He earned his M.D. from SUNY Health Science Center at Syracuse and MBA from the Isenberg School of Management at the University of Massachusetts Amherst. He completed a residency in Obstetrics & Gynecology at SUNY HSC at Syracuse and a fellowship in Medical Genetics at the National Institutes of Health. “It’s a great privilege to join the iECURE team of incredibly successful and seasoned biopharma professionals who have a long track record of developing approved life-altering treatments, while also having an opportunity to collaborate with one of the world’s premier centers of leadership and innovation in the field of genetic therapeutics,” said Dr. Cohn. “They are at the forefront of advancing innovative approaches to gene editing that hold great promise for patients in need, and at this important time of growth and development, I look forward to working with the team and leading our clinical efforts in our goal to successfully treat rare genetic disorders including OTC, CTLN1, and PKU.” About iECURE iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com and follow on LinkedIn .